About the Company
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ALNY News
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam Pharmaceuticals gets grant for novel cationic lipids for lipid nanoparticles with oligonucleotides
Discover how Alnylam Pharmaceuticals' patented cationic lipids revolutionize siRNA delivery, reducing liver toxicity and enhancing efficacy. Explore the unique compound formula and structural ...
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
One stock that might be an intriguing choice for investors right now is Alnylam Pharmaceuticals, Inc. ALNY. This is because ...
How Is The Market Feeling About Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's ALNY short percent of float has fallen 9.57% since its last report. The company recently reported ...
Ahead of Alnylam's key heart disease readout, experts say Pfizer rival would be hard to displace
As a closely watched readout from Alnylam Pharmaceuticals' Amvuttra in the rare heart disease transthyretin amyloid ...
Analysts Express Confidence in Alnylam's Hypertension Drug Despite Mixed Trial Data
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) presented results from the KARDIA-2 Phase 2 study, which evaluated the efficacy ...
Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY
NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam ...
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May ...
Biogen beats analyst estimates with Leqembi boost, Roche sales fall in Q1
In addition to Leqembi, Biogen’s postpartum depression drug Zurzuvae generated $12 million in quarterly revenues, topping the ...
Chugai in-licenses RNAi therapeutic zilebesiran for hypertension with high cardiovascular risk
Chugai in-licenses RNAi therapeutic zilebesiran for hypertension with high cardiovascular risk: Tokyo Saturday, April 20, 2024, 14:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd. ann ...
Rx Rundown: Vertex Pharmaceuticals, Bristol Myers Squibb, Novartis and more
Vertex Pharmaceuticals announced its biggest M&A play yet, acquiring Alpine Immune Sciences for $4.9 billion. MM+M is proud ...
Loading the latest forecasts...